Impact of primary kidney disease on the effects of empagliflozin in patients with chronic kidney disease: secondary analyses of the EMPA-KIDNEY trialPK Judge, A. Q. Adeleke, SJ Hauske et al.|The Lancet Diabetes & Endocrinology|2023Cited by 107